Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

Executive Summary

$465m settlement with DOJ to resolve questions about EpiPen's classification is roughly the size of autoinjector's Medicaid and Medicare sales last year; Mylan expects to enter corporate integrity agreement.


Related Content

Medicare Part D Drug Price Policies May Offer Financial Trade-Offs
Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement
EpiPen Pricing Got Mylan In Hot Water; Now Sanofi Is Taking Firm To Court
Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts